Skip to main content

RAPID3 in Assessing Psoriatic Arthritis

Nov 18, 2021 4:44 pm

My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.

While developed and tested largely in rheumatoid arthritis (RA) patients, this tool that measures pain, function and patient global assessment (3 of the 7 core set measures in the ACR20 and other activity scores) has been applied to other diseases and shown to be successful.  It has been developed for daily assessments but has also been used as a clinical trial outcome measure. Surprisingly this tool has also shown utility in axial spondyloarthritis, osteoarthritis, lupus and gout.

In Abstract #0633, Bergman and colleagues examined its utility in psoriatic arthritis (PsA). In their study of 100 PsA patients, they also looked at CDAI, cDAPSA and DAPSA they showed that RAPID3 was strongly correlated with these other measures oft applied to PsA. 

Dr. Meral El Ramahi gives her take on this RAPID3 focused report from ACR21. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.